Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamibarotene plus paclitaxel/carboplatin versus placebo plus paclitaxel/carboplatin as first-line treatment in advanced non-small cell lung cancer
2011-004982-33Phase 2Terminated
- Sponsor
- LadRx
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Tamibarotene + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms). Primary endpoint: Progression-free survival. Started Feb 2012; status: terminated.
02
Drugs
tamibarotene
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-004982-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004982-33.